Search results
Results from the WOW.Com Content Network
Generally, drugs outlined within the ATC code N04 should be included in this category. Please see WP:PHARM:CAT for more information. Wikimedia Commons has media related to Antiparkinsonian agents .
XP-21279 is a sustained-release levodopa (L-DOPA) prodrug and hence a dopamine precursor and non-selective dopamine receptor agonist which was under development for the treatment of Parkinson's disease. [4] [1] [3] It is taken by mouth. [1] [2] [3]
Dopamine agonists are mainly used in the treatment of Parkinson's disease. [2] The cause of Parkinson's is not fully known but genetic factors, for example specific genetic mutations, and environmental triggers have been linked to the disease. [4] In Parkinson's disease dopaminergic neurons that produce the neurotransmitter dopamine in the ...
Dopamine receptors are a class of G protein-coupled receptors that are prominent in the vertebrate central nervous system (CNS) and are implicated in many neurological processes, including motivational and incentive salience, cognition, memory, learning, and fine motor control, as well as modulation of neuroendocrine signaling.
ATC code N04 Anti-parkinson drugs is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products. [1] [2] [3] Subgroup N04 is part of the anatomical group N Nervous system. [4]
One dopamine precursor, Levodopa, was the first drug approved specifically for Parkinson's disease. [2] DRT increases dopamine in the brain to optimal levels in order to return motor skills, impulsivity, and decision making to normal function. [3] Although DRT can improve motor skills and decision making in patients with mild to severe ...
Dihydroergocryptine has been shown to be particularly effective as monotherapy in the early stages of Parkinson's disease.Initial monotherapy with a dopamine agonist (other examples include pergolide, pramipexole, and ropinirole) is associated with reduced risk for motor complications in Parkinson patients relative to levodopa. [2]
Ropinirole, sold under the brand name Requip among others, is a medication used to treat Parkinson's disease (PD) and restless legs syndrome (RLS). [3] It is taken by mouth. [4] Common side effects include sleepiness, vomiting, and dizziness. [4] Serious side effects may include pathological gambling, low blood pressure with standing and ...